Welcome to our dedicated page for Provectus Biopha SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Provectus Biopharmaceuticals, Inc. (PVCT) SEC filings page on Stock Titan is intended to centralize access to the company’s U.S. regulatory disclosures as they become available, alongside AI-generated insights. Provectus describes itself as a clinical-stage biotechnology company developing immunotherapy medicines based on halogenated xanthenes, led by its rose bengal sodium platform and investigational drug PV-10. For investors and researchers, SEC documents are a key source of information on how this scientific and clinical activity is reflected in the company’s formal reporting.
While no specific filings are listed in the data provided here, typical SEC reports for a company like Provectus can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, as well as proxy statements related to annual stockholder meetings. These documents may discuss clinical trial progress, research collaborations, risk factors, financing activities, and other matters relevant to a clinical-stage biotechnology business focused on oncology, dermatology, ophthalmology, wound healing, hematology, infectious diseases, and tissue repair research.
Stock Titan’s platform enhances these filings with AI-powered summaries designed to explain complex sections in clearer language. When filings are available, users can quickly see highlights from lengthy reports, such as key updates on investigational programs like PV-10, descriptions of the rose bengal sodium-based pipeline, and discussions of corporate structure or founded entities such as VisiRose. The platform also supports real-time updates as new SEC documents are posted to the EDGAR system.
For those analyzing PVCT, this page offers a single location to review Provectus’s regulatory history as it is reported, with tools that help interpret dense disclosures and place them in the context of the company’s stated focus on halogenated xanthene-based immunotherapy medicines.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note that can be converted into 17,471 shares of Series D-1 Convertible Preferred Stock. The note may be voluntarily converted into Series D-1 Preferred at a price of $2.862 per share at any time while outstanding.
According to the disclosure, any outstanding principal and interest on the note will automatically convert into Series D-1 Preferred at the same $2.862 price per share twelve months after the note’s issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert to common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals, Inc. files its 2025 annual report outlining a broad rose bengal sodium (RBS)–based immunotherapy platform, spanning oncology, dermatology, ophthalmology and multiple early non-clinical programs. The company highlights an extensive U.S. and international patent estate supporting its pharmaceutical-grade RBS and PV‑10/PH‑10 candidates.
The report warns of substantial doubt about the company’s ability to continue as a going concern, citing an accumulated net loss of approximately $263 million since inception, a cash balance of $251,291 and a working capital deficit of $6,329,503 as of December 31, 2025. Management states that additional capital will be required in 2026 and beyond to advance clinical trials and operations.
As of June 30, 2025, the aggregate market value of common equity held by non‑affiliates was $30,585,685, based on a price of $0.075 per share. There were 420,279,879 shares of common stock outstanding as of March 23, 2026. The company also discloses cybersecurity, environmental and human‑capital practices, including a six‑person full‑time workforce and use of cloud‑based, third‑party monitored IT systems.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. The note allows him to convert outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at $2.862 per share, with automatic conversion into Series D-1 Preferred twelve months after the issue date. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note as a derivative security. The note was issued under the company’s 2025 Financing and does not immediately involve common shares, but it can later convert into equity.
The footnotes state that the outstanding principal and interest of the note may be converted into shares of Series D-1 Convertible Preferred Stock at a price per share of $2.862, either voluntarily at any time or automatically twelve months after the issue date. Each Series D-1 Preferred share is in turn convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing reported the grant of an 8% unsecured convertible promissory note. The note may be voluntarily converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share while it is outstanding.
The outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at $2.862 per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-cash conversion of an 8% unsecured convertible promissory note into 47,180 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on February 20, 2026.
Each Series D-1 Preferred share is convertible into 10 common shares and will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation. Following this transaction, Pershing directly owned 2,660,987 Series D-1 Preferred shares.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. This derivative security allows him to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share at any time while the note is outstanding.
The footnotes state that, twelve months after the note’s issue date, the outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at the same $2.862 conversion price. Each Series D-1 Preferred share is then convertible into 10 shares of Provectus common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note from the company on February 12, 2026. The note has a principal amount of $30,000 and may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.
The outstanding principal and interest on the note will automatically convert into Series D-1 preferred stock twelve months after the note’s issue date. Each Series D-1 preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
Pershing Edward reported open-market purchase transactions in a Form 4 filing for PVCT. The filing lists transactions totaling 34,940 shares at a weighted average price of $2.86 per share. Following the reported transactions, holdings were 2,613,807 shares.